
    
      This is a multi-center, randomized, double-blind, placebo-controlled, parallel group,
      efficacy and safety study of Staccato Loxapine or placebo in treating acute agitation in
      patients with schizophrenia or bipolar disorder (manic or mixed episodes) as defined by DSM-V
      criteria.Patients may receive up to 3 doses of study drug in a 24-hour period, depending on
      their clinical status. The primary endpoint is the change from baseline in the PANSS
      (Positive and Negative Symptom Scale) Excited Component (also known as PEC) score, performed
      at 2 hours after the first dose.
    
  